Stocktoria
Verrica Pharmaceuticals Inc. VRCA
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-06-15
Verrica Pharmaceuticals Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -34.2% | -871.3% | -1283.4% | -235.8% | -257.6% |
| Net margin | -50.3% | -1012.1% | -1307.5% | -271.1% | -292.3% |
| FCF margin | -49.5% | -805.6% | -759.9% | -209.8% | -237.2% |
| Return on assets | -37.9% | -141.5% | -82.1% | -54.8% | -43.8% |
| Return on equity | -72.3% | 776.7% | -339.0% | -61.2% | -107.6% |
| Debt / equity | 0.00× | -3.14× | 2.17× | 0.00× | — |
| Current ratio | 2.59 | 1.76 | 4.55 | 11.31 | 1.61 |
| Revenue growth | 370.2% | 47.7% | -43.3% | -24.7% | — |
Source: SEC EDGAR filings · CIK 0001660334 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.